Pharma companies should not repeat the inequities seen in Covid-19 treatments

In The Hindu's BusinessLine, Jyothi Datta reports on the findings of the third Antimicrobial Resistance Benchmark.

A news feature in The Hindu's BusinessLine delves into the findings of the 2021 Antimicrobial Resistance Benchmark, exploring the the report's analysis of access strategies, responsible manufacturing, and R&D.

“Pharma companies must ensure they do not repeat the unacceptable inequities seen in Covid (treatments), when it comes to antibiotics and the fight against superbugs," Access to Medicine Foundation CEO Jayasree Iyer told the publication.

The article particularly examines the Indian companies in scope of the Benchmark, saying: "A clutch of generic Indian companies also featured in the report, for efforts to ensure cleaner manufacture of antibiotics, besides making sure they were not promoted unnecessarily."

Click here to read the full article.